Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood

Innate Immunity

Volumn 20, Issue 1, 2014, Pages 68-77

  Egge, Kjetil H ^a   Thorgersen, Ebbe B ^a   Lindstad, Julie K ^a   Pharo, Anne ^a   Lambris, John D ^b   Barratt Due, Andreas ^a   Mollnes, Tom E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

c3; CD14; complement; cytokines; Escherichia coli; human; post challenge

Indexed keywords

CD14 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; COMPSTATIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPIRUDIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MYELOPEROXIDASE; TERMINAL COMPLEMENT COMPLEX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; INCUBATION TIME; INFLAMMATION; NONHUMAN;

C3; CD14; COMPLEMENT; CYTOKINES; ESCHERICHIA COLI; HUMAN; POST-CHALLENGE;

ANTIBODIES, BLOCKING; ANTIGENS, CD14; BLOOD; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINES; DRUG COMBINATIONS; DRUG SYNERGISM; ESCHERICHIA COLI; HOT TEMPERATURE; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; PEPTIDES, CYCLIC; PEROXIDASE; SEPSIS;

EID: 84891335424     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913482993     Document Type: Article

References (45)

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 ; 348: 1546-1554
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med. 2001 ; 29: S109 - S116
3. Karlsson S, Varpula M, Ruokonen E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007 ; 33: 435-443
4. Kumar G, Kumar N, Taneja A, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest. 2011 ; 140: 1223-1231
5. Focus on sepsis. Nat Med. 2012 ; 18: 997-997
6. Williams SC. After Xigris, researchers look to new targets to combat sepsis. Nat Med. 2012 ; 18: 1001-1001
7. Marshall JC. Sepsis: rethinking the approach to clinical research. J Leukoc Biol. 2008 ; 83: 471-482
8. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002 ; 20: 197-216
9. Matzinger P. The danger model: a renewed sense of self. Science. 2002 ; 12 (296). 301-305
10. Kohl J. The role of complement in danger sensing and transmission. Immunol Res. 2006 ; 34: 157-176
11. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998 ; 282: 2085-2088
12. Akashi-Takamura S, Miyake K. TLR accessory molecules. Curr Opin Immunol. 2008 ; 20: 420-425
13. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol. 2012 ; 12: 168-179
14. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990 ; 249: 1431-1433
15. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008 ; 42: 145-151
16. Rossol M, Heine H, Meusch U, et al. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol. 2011 ; 31: 379-446
17. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. Trends Immunol. 2009 ; 30: 83-90
18. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010 ; 11: 785-797
19. Sarma JV, Ward PA. The complement system. Cell Tissue Res. 2011 ; 343: 227-235
20. Walport MJ. Complement. First of two parts. N Engl J Med. 2001 ; 344: 1058-1066
21. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol. 2001 ; 38: 175-187
22. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004 ; 4: 133-142
23. Ward PA, Gao H. Sepsis, complement and the dysregulated inflammatory response. J Cell Mol Med. 2009 ; 13: 4154-4160
24. Mollnes TE, Christiansen D, Brekke OL, et al. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv Exp Med Biol. 2008 ; 632: 253-263
25. Rittirsch D, Flierl MA, Nadeau BA, et al. Functional roles for C5a receptors in sepsis. Nat Med. 2008 ; 14: 551-557
26. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010 ; 31: 154-163
27. Hawlisch H, Kohl J. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol Immunol. 2006 ; 43: 13-21
28. Thorgersen EB, Hellerud BC, Nielsen EW, et al. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J. 2010 ; 24: 712-722
29. Brekke OL, Christiansen D, Fure H, et al. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol Immunol. 2008 ; 45: 3804-3813
30. Lappegard KT, Christiansen D, Pharo A, et al. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci USA. 2009 ; 106: 15861-15866
31. Mollnes TE, Brekke OL, Fung M, et al. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood. 2002 ; 100: 1869-1877
32. Qu H, Ricklin D, Bai H, et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. Epub ahead of print 17 June 2012.
33. Mollnes TE, Lea T, Froland SS, et al. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol. 1985 ; 22: 197-202
34. Mollnes TE, Redl H, Hogasen K, et al. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol. 1993 ; 91: 295-300
35. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010 ; 140: 805-820
36. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 ; 124: 783-801
37. Barratt-Due A, Thorgersen EB, Lindstad JK, et al. Ornithodoros moubata complement inhibitor is an equally effective C5 inhibitor in pigs and humans. J Immunol. 2011 ; 187: 4913-4919
38. Thorgersen EB, Pharo A, Haverson K, et al. Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood. Infect Immun. 2009 ; 77: 725-732
39. Cauvi DM, Song D, Vazquez DE, et al. Period of irreversible therapeutic intervention during sepsis correlates with phase of innate immune dysfunction. J Biol Chem. 2012 ; 287: 19804-19815
40. Huber-Lang MS, Riedeman NC, Sarma JV, et al. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 2002 ; 16: 1567-1574
41. Huber-Lang MS, Sarma JV, McGuire SR, et al. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J. 2001 ; 15: 568-570
42. Brekke OL, Christiansen D, Fure H, et al. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc Biol. 2007 ; 81: 1404-1413
43. Zhang X, Kimura Y, Fang C, et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood. 2007 ; 110: 228-236
44. Hellerud BC, Stenvik J, Espevik T, et al. Stages of meningococcal sepsis simulated in vitro, with emphasis on complement and Toll-like receptor activation. Infect Immun. 2008 ; 76: 4183-4189
45. Christiansen D, Brekke OL, Stenvik J, et al. Differential effect of inhibiting MD-2 and CD14 on LPS- versus whole E. coli bacteria-induced cytokine responses in human blood. Adv Exp Med Biol. 2012 ; 946: 237-251